8-KAccepted Nov 16, 5:12 PM ET
Boumarang Inc: Remeasures Nuvora investment and restates Q2 2026 results
Accepted (ET)
5:12 PM
Nov 16, 2026
Filed
Nov 16, 2026
Documents
12
Size
145.3 KB
Summary
Boumarang Inc: Remeasures Nuvora investment and restates Q2 2026 results
What happened
- The board, acting in its audit committee capacity, concluded on Nov 6, 2026 that the previously issued unaudited consolidated financial statements for the three and six months ended Jun 30, 2026 included in the Form 10-Q filed Aug 11, 2026 should no longer be relied upon.
- The board identified an error in the measurement of the Company’s investment in Nuvora Energy, Inc. After a May 2026 Nuvora equity financing of $500,000 at $3.00 per share, Boumarang remeasured its 1,000,000 Nuvora shares from $2.00 per share ($2,000,000) to $3.00 per share ($3,000,000) and recorded, as of May 31, 2026, a $1,000,000 increase to investment in private equities and a corresponding $1,000,000 non-cash unrealized gain in other income (expense).
- The Company filed Amendment No. 1 on Form 10-Q/A for the quarter ended Jun 30, 2026 with the SEC on Nov 6, 2026.
Key details
- Net income for the three months ended Jun 30, 2026, as restated: $450,136 (previously reported net loss of $549,864).
- Net loss for the six months ended Jun 30, 2026, as restated: $64,222 (previously reported net loss of $1,064,222).
- Balance sheet changes as of Jun 30, 2026, as restated: investment in private equity securities $3,000,000 (previously $2,000,000); accumulated deficit $3,058,542 (previously $4,058,542); total stockholders’ equity $20,096,458 (previously $19,096,458).
- Management identified a material weakness in disclosure controls and procedures and internal control over financial reporting related to the matters giving rise to the restatement. No income tax effect was recorded due to a full valuation allowance against deferred tax assets. The restatement did not affect reported cash, total liabilities, operating loss, or net cash flows.
Why it may matter
- Item reported: Item 4.02, non-reliance on previously issued financial statements, which covers the restatement of the Q2 2026 financial statements and related internal control matters. The filing describes the remeasurement, the accounting correction, and the identified material weakness.
- The filing does not show why the company acted.